Project WAVE

Inspiration Healthcare is a global medical technology company specializing in innovative products for critical care and operating theaters, with a primary focus on neonatal intensive care. The company's flagship development program, code-named Project WAVE, is a novel, non-invasive respiratory device designed to reduce intermittent hypoxia in premature infants. Acquired under license from the University of California, Los Angeles (UCLA) in 2018, the technology offers a non-pharmaceutical approach to treating apnoea of prematurity. Inspiration Healthcare is currently advancing Project WAVE through clinical trials in the UK, having recruited its first patient in 2021. The company is publicly traded on the London Stock Exchange (AIM) and operates through several subsidiaries, including SLE and Viomedex.